The fundamental conclusions of the primary analysis were confirmed in that there was no survival benefit overall for patients with 1 to 3 metastases ; however , there was a benefit for the subset of patients with GPA 3.5 to 4.0 ( median survival time [ MST ] for WBRT + SRS vs WBRT alone was 21.0 versus 10.3 months , P = .05 ) regardless of the number of metastases .